Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. Thiery-Vuillemin A, et al. Among authors: fizazi k. ESMO Open. 2021 Apr;6(2):100089. doi: 10.1016/j.esmoop.2021.100089. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33740734 Free PMC article.
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366
Combining docetaxel with estramustine: back to the future?
Oudard S, Eymard JC, Fizazi K. Oudard S, et al. Among authors: fizazi k. J Clin Oncol. 2009 Mar 1;27(7):1148-9; author reply 1149-50. doi: 10.1200/JCO.2009.21.2274. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171697 No abstract available.
New agents in metastatic prostate cancer.
Fizazi K, Massard C. Fizazi K, et al. Eur J Cancer. 2009 Sep;45 Suppl 1:379-80. doi: 10.1016/S0959-8049(09)70056-5. Eur J Cancer. 2009. PMID: 19775638 No abstract available.
[New drugs in metastatic castration-resistant prostate cancer].
Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Among authors: fizazi k. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.
[Update on the use of estramustin in metastatic prostate cancer].
Culine S, Drouet L, Eymard JC, Fizazi K, Gravis G, Hennequin C, Oudard S, Ravery V, Zerbib M. Culine S, et al. Among authors: fizazi k. Prog Urol. 2010 Jan;20(1):24-9. doi: 10.1016/j.purol.2009.08.039. Epub 2009 Oct 14. Prog Urol. 2010. PMID: 20123524 French.
541 results